Quick Facts

• Relief of Nausea and Vomiting: Nomesis is used to provide relief from the symptoms of nausea (feeling sick) and vomiting (being sick).

---

Nomesis, which contains the active substance domperidone, is primarily indicated for the relief of the symptoms of nausea and vomiting. It is utilized for short-term management, typically for a duration not exceeding one week.

This medication is intended to address these symptoms, which may arise from various underlying causes. By working on specific receptors, it helps to prevent the feeling of sickness and the act of vomiting.

While domperidone may have previously been used for other gastrointestinal discomforts, the therapeutic focus has been refined. The use of domperidone-containing medicines is restricted to the symptomatic relief of nausea and vomiting. Usage is typically limited to the lowest effective dose for the shortest time necessary to control these specific symptoms.

The eligibility for Nomesis (Domperidone) is strictly defined by regulatory authorities and centers on age, underlying health conditions, and concomitant medications.

Populations for Whom Use is Contraindicated

Domperidone is strictly contraindicated for several patient groups due to regulatory warnings about cardiac risk. This includes individuals with:

• Known existing prolongation of cardiac conduction intervals (QTc) or underlying cardiac diseases, such as congestive heart failure.
• Significant electrolyte disturbances (e.g., hypokalemia).
• Moderate or severe hepatic impairment (liver disease).
• Prolactin-releasing pituitary tumour (prolactinoma).
• Gastrointestinal conditions where motility stimulation is harmful (e.g., hemorrhage, obstruction, or perforation).
• Concomitant use with QT-prolonging medicines or potent CYP3A4 inhibitors.

Age and Conditional Use Rules

• Age-Group Eligibility: Use is restricted to adults and adolescents aged 12 years and older who weigh 35 kg or more. The medicine is not licensed for children younger than 12 or those weighing less than 35 kg. Older adults (over 60) are advised to use the medicine with caution due to observed higher cardiac risk.
• Organ Function Restriction: Patients with severe renal impairment must have their dosing frequency reduced and be regularly reviewed. Use in mild hepatic impairment requires no dose modification.
• Pregnancy and Lactation: Use during pregnancy is conditional, permitted only when the anticipated benefit justifies the potential risk. Domperidone is excreted in human milk; the regulatory status requires a decision to discontinue breastfeeding or discontinue therapy.

The official regulatory interaction profile for Nomesis (domperidone) is primarily structured by high-risk contraindicated combinations stemming from pharmacokinetic and pharmacodynamic concerns.

The main metabolic pathway is through the cytochrome P450 isoenzyme CYP3A4. The co-administration of domperidone with potent CYP3A4 inhibitors (e.g., systemic azole antifungals, certain macrolide antibiotics, HIV protease inhibitors) is strictly prohibited, as these agents decrease metabolism, leading to a significant increase in plasma exposure and associated risk.

Similarly, combination with any other medicinal product known to prolong the QTc interval is contraindicated due to the additive risk of serious ventricular arrhythmias. Specific drug classes listed include certain antiarrhythmics (Class IA and III) and certain antipsychotics. The non-medicinal substance grapefruit juice is also contraindicated due to its ability to increase domperidone exposure.

Administration Timing and Absorption

Interactions that alter absorption require administration separation. Antacids and antisecretory agents reduce the oral bioavailability of domperidone and must not be taken at the same time. The regulatory profile also notes that anticholinergic drugs may compromise the prokinetic effects of domperidone. The risk of serious ventricular arrhythmias is observed to be higher in patients older than 60 years and in patients with pre-existing electrolyte disturbances.

Domperidone's activity is defined by its role as a functional antagonist of Dopamine mathbfD2 and mathbfD3 receptors, primarily in the body's periphery. This molecular action initiates two distinct physiological cascades focused on modulating the emetic reflex and increasing gastrointestinal motility.

Peripheral mathbfD2 Receptor Blockade for Emetic Reflex Modulation

This mechanism concerns the emetic reflex pathway by targeting the Chemoreceptor Trigger Zone (CTZ). By blocking mathbfD2 receptors in the mathbfCTZ—a sensory area located outside the Blood-Brain Barrier (BBB)—the drug prevents excitatory dopamine signals from initiating the vomiting reflex. This action functionally interrupts the emetic signal cascade.

---

Disinhibition for Increased Gastric Motility

This domain explains the prokinetic action through the Enteric Nervous System (ENS). Dopamine normally exerts an inhibitory tone on the gut's movement by suppressing acetylcholine (Ach) release; Domperidone's mathbfD2 blockade removes this inhibitory brake. The resulting unimpeded Ach release increases the coordination and strength of gastric and duodenal peristalsis, leading to accelerated gastric emptying.

How to Use Nomesis (Domperidone)

The use of Nomesis (domperidone) follows specific administration guidelines to ensure precise usage patterns. The medicine is primarily intended for oral administration, available as tablets (typically 10 mg) and as an oral solution or suspension.

Administration Parameter	General Guidelines
Standard Adult Dose (≥ 35 kg)	10 mg per dose
Maximum Daily Dose	30 mg total per day
Frequency Pattern	Up to three times per day
Timing	Recommended to be taken 15 to 30 minutes before meals
Maximum Duration	Must not exceed seven days total treatment course

Administration is structured by an interval of approximately eight hours between doses, adhering to the maximum daily limit. The treatment is intended for short-term use only, and the total duration must not extend beyond one week. For proper administration, tablets must be swallowed whole with water.

In the event of a missed dose, the dose should be omitted entirely, and the regular schedule should be resumed; the dose must not be doubled. Furthermore, specialized adjustments are indicated for certain populations; for instance, the dosing frequency is reduced for patients with severe renal impairment.

Nomesis (Domperidone): Recent Clinical Evidence

Clinical research on domperidone, a dopamine receptor antagonist with antiemetic and prokinetic properties, focuses primarily on its effectiveness in treating symptoms associated with gastrointestinal motility disorders.

---

Efficacy Findings

Studies have assessed domperidone's role in the management of chronic nausea and vomiting, particularly for patients with conditions such as gastroparesis or refractory gastroesophageal reflux disease (GERD).

• Gastroparesis: Research conducted under controlled protocols, often for patients who did not respond to other therapies, explored symptom reduction. One study observed that in a select cohort of gastroparesis patients, the mean reported severity of vomiting and nausea showed a reduction after long-term treatment.
• Pediatric Acute Gastroenteritis: A multicenter, placebo-controlled study examining domperidone in children aged 6 months to 12 years with acute gastroenteritis did not show a difference in reducing vomiting episodes or nausea compared to placebo plus oral rehydration therapy. This lack of difference led to a revision of its authorized use in some regions for this population.
• GERD Combination: A systematic review and meta-analysis examined domperidone when combined with a Proton Pump Inhibitor (PPI) for GERD treatment. The analysis found that the combination resulted in a reduction in global GERD symptoms compared to PPI monotherapy.

---

Safety and Tolerability

Safety data is evaluated in all clinical settings, with particular attention to potential cardiovascular effects.

• Cardiac Monitoring: Since reports of possible cardiotoxicity, clinical trials typically incorporate frequent electrocardiograms (ECGs) to monitor for QTc prolongation. Certain studies of long-term, high-dose use in highly selected gastroparesis patients observed asymptomatic, non-meaningful QTc prolongation in some participants.
• Exclusion Criteria: Patients with pre-existing cardiovascular conditions, a history of dangerous arrhythmias, or significant electrolyte disturbances were generally excluded from specific domperidone trials designed to assess long-term use.

Common questions about Nomesis (Domperidone) (FAQ)

---

Q: How is Nomesis different from other anti-nausea medications like Metoclopramide?

A: Official information states that Nomesis (Domperidone) is a peripheral dopamine antagonist. This means its action is primarily concentrated outside the central nervous system (CNS) because it does not readily cross the blood-brain barrier. This characteristic is key to its pharmacological profile, as other anti-nausea medications may act more centrally.

Q: Are there specific studies about Nomesis use in children?

A: Studies have been conducted on Domperidone use in children. However, due to safety concerns and a lack of clear efficacy in certain conditions, regulatory bodies often restrict its use to adolescents aged 12 years and older who weigh at least 35 kg. In many regions, the authorized use for children is restricted or subject to specific regulatory changes due to safety concerns and trial results.

Q: Why is Nomesis available over-the-counter in some countries but prescription-only in others?

A: Regulatory classification (prescription-only vs. over-the-counter) is a decision made by each national health authority based on local reviews of the medicine’s risks and benefits. Major regulatory actions often follow reviews focused on cardiac safety, which leads to variation in availability rules internationally.

Q: What should a patient do if they accidentally take more Nomesis than intended?

A: Official product information states that symptoms of an overdose can include disorientation, loss of balance, somnolence (drowsiness), and uncontrolled movements. It is recommended to seek medical advice right away if an overdose is suspected.

Q: Is it safe to use Nomesis during the first trimester of pregnancy?

A: Regulatory documents state that use during pregnancy is conditional and is generally permitted only when the anticipated benefit justifies the potential risk. Safety information is not typically stratified by trimester. The decision to use Nomesis during pregnancy must be made by a healthcare provider.

Q: Can Nomesis interact with high blood pressure medications?

A: Nomesis should not be used with any medication known to prolong the QTc interval or affect heart rhythm. Patients taking blood pressure medications should consult their healthcare provider, although common antihypertensives are not usually listed as absolute contraindications in the official label.

Q: Is Nomesis similar to antacids or proton pump inhibitors (PPIs)?

A: Nomesis is fundamentally different; it is classified as a prokinetic agent that speeds up gastrointestinal movement. Antacids and PPIs are antisecretory agents that reduce or neutralize stomach acid. Official information advises against taking Nomesis at the same time as antacids or antisecretory agents, as these products can reduce the amount of Domperidone the body absorbs.

Q: How is Nomesis stored, and does it need to be refrigerated?

A: Official storage instructions require Nomesis to be kept at a controlled room temperature, typically below 25°C or 30°C. It must be protected from light and moisture and should not be frozen. It must also be kept in its original packaging and out of the sight and reach of children.

Q: Does Nomesis work instantly, or does it take a few hours to feel the effect?

A: Pharmacokinetic data suggests that the active ingredient, Domperidone, reaches its highest concentration in the bloodstream (peak plasma levels) typically between 30 and 60 minutes after taking an oral dose. This indicates that the therapeutic effects usually begin to be felt within this one-hour timeframe.

Q: Can Nomesis (Domperidone) help with bloating and feeling full quickly?

A: Nomesis is known to have a prokinetic effect, which helps speed up the stomach’s emptying process. However, regulatory authorities have restricted its authorized use primarily to relieving feelings of nausea and vomiting. It is not generally indicated for non-specific symptoms like general bloating or heartburn alone.

Q: Is Nomesis known to cause drowsiness or affect alertness?

A: Regulatory documents list somnolence (drowsiness) as a reported adverse reaction, though its frequency is not known. Due to the potential for dizziness or drowsiness, individuals are advised to exercise caution when driving or operating machinery.

Q: Does Nomesis lose its effectiveness if taken for a long period?

A: Regulatory authorities strictly limit Nomesis to a short-term treatment course, primarily due to safety concerns regarding the heart. This limitation is in place primarily due to safety concerns regarding the heart, and long-term effectiveness is not generally supported or approved.

Q: What is the difference between Domperidone and the brand name Nomesis?

A: Domperidone is the name of the active pharmaceutical ingredient (API) in the medicine. Nomesis is a brand name under which the product containing Domperidone is marketed and sold by a specific manufacturer.

Q: Is it normal to feel a bit light-headed after starting Nomesis?

A: Official safety information lists dizziness as an uncommon side effect. If light-headedness or dizziness is persistent or concerning, the symptom should be discussed with a healthcare professional.

Q: What are the restrictions on driving or operating machinery while on Nomesis?

A: Because adverse reactions like somnolence (drowsiness) and dizziness have been reported, caution should be exercised. Individuals who experience these side effects are advised not to drive or operate complex machinery.

Q: Are there any long-term side effects that people who use Nomesis should be aware of?

A: Regulatory warnings specifically highlight that the risk of serious cardiac events is increased with high daily doses and with longer periods of treatment. This is the main reason why Nomesis is limited to the shortest possible duration of therapy.

Q: Why do some people experience restless legs or movements while on Nomesis?

A: The drug’s mechanism of action as a dopamine antagonist means that extrapyramidal side effects (which can include involuntary movements or restlessness) are a known possibility, particularly noted in infants and young children. If these effects occur, they should be brought to the attention of a healthcare provider.

Q: Can Nomesis cause changes in weight or appetite?

A: Changes in appetite have been reported as a rare side effect in some post-marketing surveillance. However, regulatory documents do not provide consistent or conclusive data directly linking Nomesis to significant or general changes in weight.

Q: What research supports the use of Nomesis for diabetic gastroparesis?

A: Studies have been conducted to evaluate its effectiveness for conditions like gastroparesis, particularly in patients who have not responded to other treatments. In some jurisdictions, it is available through special regulatory programs specifically for managing refractory gastrointestinal conditions, including diabetic gastroparesis.

Q: What is the research history of Nomesis and its initial intended use?

A: Domperidone was first authorized in several countries in the late 1970s. Since then, official reviews have led to restrictions, notably limiting its use primarily to nausea and vomiting due to evolving understanding of its cardiac safety risks.

Q: Are there specific foods or drinks to avoid while taking Nomesis?

A: Grapefruit juice is specifically contraindicated because official sources warn that its consumption can increase the concentration of Domperidone in the bloodstream, raising the risk of serious side effects.

Storage and Protection Requirements

Nomesis (Domperidone) must be stored at a controlled room temperature, generally between 15 C and 30 C, or in some regions, below 25 C. The medicine requires protection from environmental factors; it must be protected from light and moisture and should not be frozen.

To ensure product stability, the medicine must be kept in its original package and the container should remain tightly closed when not in use. A critical safety requirement is that Nomesis must always be kept out of the sight and reach of children.

Official Disposal Instructions

Regulatory agencies mandate that unused or expired Nomesis must not be thrown into household trash or wastewater. The correct procedure is to dispose of the medicine through a pharmacy take-back program or return it to a designated collection point for pharmaceutical waste.